General Notices

• Notice of Extension of the Expiration Date for PAR-18-884 Novel Approaches to Safe, Non-Invasive, Real Time Assessment of Human Placenta Development and Function Across Pregnancy (R01 - Clinical Trial Not Allowed)
  (NOT-HD-20-037)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Extension of the Expiration Date for PAR-18-885 Novel Approaches to Safe, Non-Invasive, Real Time Assessment of Human Placenta Development and Function Across Pregnancy (R21 - Clinical Trial Not Allowed)
  (NOT-HD-20-038)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Technical and Business Assistance (TABA) Needs Assessment Program for National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Awardees
  (NOT-OD-21-023)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• : Notice of NIA Withdrawal from Participation in NOT-OD-20-129 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome
  (NOT-AG-20-055)
  National Institute on Aging
  

• Notice of Change: Correction of Eligibility Information for RFA-AI-20-056 Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)
  (NOT-AI-21-003)
  National Institute of Allergy and Infectious Diseases
  

• Notice of NCI's Withdrawal from Participation in PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"
  (NOT-CA-21-014)
  National Cancer Institute
  

• Notice of Participation of the National Institute on Drug Abuse(NIDA) in PA-19-042, "Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)"
  (NOT-DA-20-095)
  National Institute on Drug Abuse
  

• Notice of Participation of the National Institute on Drug Abuse(NIDA) in PA-19-050, "Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)"
  (NOT-DA-20-096)
  National Institute on Drug Abuse
  

• Notice of Correction in Key Dates for NIDA PAR-21-044, " Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)"
  (NOT-DA-21-005)
  National Institute on Drug Abuse
  

• Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-001, "Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)"
  (NOT-DA-21-009)
  National Institute on Drug Abuse
  

• Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-002, "Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)"
  (NOT-DA-21-010)
  National Institute on Drug Abuse
  

• Notice to Extend the Expiration Date for PAR-18-547, NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (NOT-DE-20-037)
  National Institute of Dental and Craniofacial Research
  

• Notice of NIDDK Participation in PA-20-190 and PA-20-176, NIH Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Required and No Independent Clinical Trial Not Allowed) Funding Opportunity Announcements
  (NOT-DK-21-002)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of NINR Participation in NOT-HL-20-737 Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases
  (NOT-NR-20-007)
  National Institute of Nursing Research
  

• Notice of Correction to NOT-OD-21-012 "Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco Regulatory Science (R01 Clinical Trial Optional)"
  (NOT-OD-21-025)
  Office of Disease Prevention
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
  (NOT-NS-21-006)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
  (NOT-NS-21-007)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33)
  (NOT-NS-21-008)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Artificial Intelligence for Multimodal Data Modeling and Bioinformatics Center (U54 Clinical Trial Not Allowed)
  (NOT-RM-21-001)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Metabolomics and Clinical Assays Center (U24)
  (NOT-RM-21-002)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Microbiome and Metagenomics Center (U24 Clinical Trial Not Allowed)
  (NOT-RM-21-003)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Dietary Assessment Center (U24 Clinical Trial Optional)
  (NOT-RM-21-006)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Clinical Centers (UG1 Clinical Trial Required)
  (NOT-RM-21-007)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Research Coordinating Center (U24 Clinical Trial Not Allowed)
  (NOT-RM-21-008)
  Office of Strategic Coordination (Common Fund)
  

Notices of Special Interest

• Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
  (NOT-AI-21-002)
  National Institute of Allergy and Infectious Diseases
  

• RESCINDED - Notice of Special Interest (NOSI): Administrative Supplement for Providing Travel Support for Awardees to Attend the Annual NIH Synthetic Biology Consortium Meeting (Admin Supp)
  (NOT-EB-20-022)
  National Institute of Biomedical Imaging and Bioengineering
  

• NOSI: Academy of Finland (AKA) National Institutes of Health (NIH) Partnership Program
  (NOT-OD-21-021)
  National Institutes of Health
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Diabetes and Digestive and Kidney Diseases
  

Funding Opportunities

• National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
  (PAR-21-033)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021
  
  

• Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
  (PAR-21-035)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first application due date for this FOA is February 5, 2021.
  
  

• NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
  (PAR-21-036)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 4, 2021; July 2, 2021; November 2, 2021; March 4, 2022; July 1, 2022; November 4, 2022; March 3, 2023; July 2, 2023; November 3, 2023
  
  

• Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
  (PAR-21-038)
  National Institutes of Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Office of Research on Women's Health
  Application Receipt Date(s): January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023
  
  

• Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)
  (PAR-21-039)
  National Institutes of Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Research on Women's Health
  Application Receipt Date(s): January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023
  
  

• Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)
  (PAR-21-045)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 4, 2021, July 2, 2021, November 2, 2021 March 4, 2022, July 1, 2022, November 4, 2022 March 3, 2023, July 2, 2023, November 3, 2023?
  
  

• Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
  (PAR-21-053)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 4, 2021, July 2, 2021, November 2, 2021 March 4, 2022, July 1, 2022, November 4, 2022 March 3, 2023, July 2, 2023, November 3, 2023
  
  

• Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)
  (PAR-21-070)
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
  (PAR-21-072)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021.
  
  

• Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)
  (PAR-21-077)
  National Institute of General Medical Sciences
  Application Receipt Date(s): November 16, 2022
  
  

• Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)
  (RFA-DK-20-030)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 3, 2021
  
  

• Continuation of the National Evaluation System for Health Technology (NEST) Coordinating Center (CC) - (U01) Clinical Trial Optional
  (RFA-FD-21-008)
  Food and Drug Administration
  Application Receipt Date(s): January 8, 2021 Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)
  (RFA-MH-21-110)
  National Institute of Mental Health
  Application Receipt Date(s): ?February 18, 2021; October 15, 2021; June 15, 2022
  
  

• Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)
  (RFA-MH-21-111)
  National Institute of Mental Health
  Application Receipt Date(s): February 18, 2021; October 15, 2021; June 15, 2022
  
  

• Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)
  (RFA-MH-21-112)
  National Institute of Mental Health
  Application Receipt Date(s): ?February 18, 2021; October 15, 2021, June 15, 2022